Literature DB >> 27476424

Identification of potent, selective KDM5 inhibitors.

Victor S Gehling1, Steven F Bellon2, Jean-Christophe Harmange2, Yves LeBlanc2, Florence Poy2, Shobu Odate2, Shane Buker2, Fei Lan2, Shilpi Arora2, Kaylyn E Williamson2, Peter Sandy2, Richard T Cummings2, Christopher M Bailey2, Louise Bergeron2, Weifeng Mao3, Amy Gustafson4, Yichin Liu4, Erica VanderPorten4, James E Audia2, Patrick Trojer2, Brian K Albrecht2.   

Abstract

This communication describes the identification and optimization of a series of pan-KDM5 inhibitors derived from compound 1, a hit initially identified against KDM4C. Compound 1 was optimized to afford compound 20, a 10nM inhibitor of KDM5A. Compound 20 is highly selective for the KDM5 enzymes versus other histone lysine demethylases and demonstrates activity in a cellular assay measuring the increase in global histone 3 lysine 4 tri-methylation (H3K4me3). In addition compound 20 has good ADME properties, excellent mouse PK, and is a suitable starting point for further optimization.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epigenetics; Histone lysine demethylase; JARID1; KDM5

Mesh:

Substances:

Year:  2016        PMID: 27476424     DOI: 10.1016/j.bmcl.2016.07.026

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

Review 1.  JARID1 Histone Demethylases: Emerging Targets in Cancer.

Authors:  Kayla M Harmeyer; Nicole D Facompre; Meenhard Herlyn; Devraj Basu
Journal:  Trends Cancer       Date:  2017-09-12

Review 2.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

Review 3.  KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.

Authors:  Besa Xhabija; Benjamin L Kidder
Journal:  Semin Cancer Biol       Date:  2018-11-16       Impact factor: 15.707

4.  KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer.

Authors:  Heng Liu; Jianhuang Lin; Wei Zhou; Renyta Moses; Zhongping Dai; Andrew V Kossenkov; Ronny Drapkin; Benjamin G Bitler; Sergey Karakashev; Rugang Zhang
Journal:  Cancer Immunol Res       Date:  2022-08-03       Impact factor: 12.020

5.  Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase.

Authors:  Samuel K McBrayer; Benjamin A Olenchock; Gabriel J DiNatale; Diana D Shi; Januka Khanal; Rebecca B Jennings; Jesse S Novak; Matthew G Oser; Alissa K Robbins; Rebecca Modiste; Dennis Bonal; Javid Moslehi; Roderick T Bronson; Donna Neuberg; Quang-De Nguyen; Sabina Signoretti; Julie-Aurore Losman; William G Kaelin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-02       Impact factor: 11.205

Review 6.  Histone demethylase JMJD2C: epigenetic regulators in tumors.

Authors:  Chengcheng Zhang; Zhongqi Wang; Qing Ji; Qi Li
Journal:  Oncotarget       Date:  2017-07-12

7.  Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.

Authors:  Anthony Tumber; Andrea Nuzzi; Edward S Hookway; Stephanie B Hatch; Srikannathasan Velupillai; Catrine Johansson; Akane Kawamura; Pavel Savitsky; Clarence Yapp; Aleksandra Szykowska; Na Wu; Chas Bountra; Claire Strain-Damerell; Nicola A Burgess-Brown; Gian Filippo Ruda; Oleg Fedorov; Shonagh Munro; Katherine S England; Radoslaw P Nowak; Christopher J Schofield; Nicholas B La Thangue; Charlotte Pawlyn; Faith Davies; Gareth Morgan; Nick Athanasou; Susanne Müller; Udo Oppermann; Paul E Brennan
Journal:  Cell Chem Biol       Date:  2017-03-02       Impact factor: 8.116

8.  Assessing histone demethylase inhibitors in cells: lessons learned.

Authors:  Stephanie B Hatch; Clarence Yapp; Raquel C Montenegro; Pavel Savitsky; Vicki Gamble; Anthony Tumber; Gian Filippo Ruda; Vassilios Bavetsias; Oleg Fedorov; Butrus Atrash; Florence Raynaud; Rachel Lanigan; LeAnne Carmichael; Kathy Tomlin; Rosemary Burke; Susan M Westaway; Jack A Brown; Rab K Prinjha; Elisabeth D Martinez; Udo Oppermann; Christopher J Schofield; Chas Bountra; Akane Kawamura; Julian Blagg; Paul E Brennan; Olivia Rossanese; Susanne Müller
Journal:  Epigenetics Chromatin       Date:  2017-03-01       Impact factor: 4.954

9.  Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer.

Authors:  Nicole D Facompre; Kayla M Harmeyer; Varun Sahu; Phyllis A Gimotty; Anil K Rustgi; Hiroshi Nakagawa; Devraj Basu
Journal:  Oncotarget       Date:  2017-12-15

10.  Synthesis of pyrazolopyrimidinones using a "one-pot" approach under microwave irradiation.

Authors:  Mark Kelada; John M D Walsh; Robert W Devine; Patrick McArdle; John C Stephens
Journal:  Beilstein J Org Chem       Date:  2018-05-28       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.